These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 33772258)

  • 1. Ceramides and other sphingolipids as drivers of cardiovascular disease.
    Choi RH; Tatum SM; Symons JD; Summers SA; Holland WL
    Nat Rev Cardiol; 2021 Oct; 18(10):701-711. PubMed ID: 33772258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceramides are fuel gauges on the drive to cardiometabolic disease.
    Wilkerson JL; Tatum SM; Holland WL; Summers SA
    Physiol Rev; 2024 Jul; 104(3):1061-1119. PubMed ID: 38300524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. You aren't IMMUNE to the ceramides that accumulate in cardiometabolic disease.
    Varre JV; Holland WL; Summers SA
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Jun; 1867(6):159125. PubMed ID: 35218934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide Metabolism in Cardiovascular Disease: A Network With High Therapeutic Potential.
    Zietzer A; Düsing P; Reese L; Nickenig G; Jansen F
    Arterioscler Thromb Vasc Biol; 2022 Oct; 42(10):1220-1228. PubMed ID: 36004640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Dark Side of Sphingolipids: Searching for Potential Cardiovascular Biomarkers.
    Di Pietro P; Izzo C; Abate AC; Iesu P; Rusciano MR; Venturini E; Visco V; Sommella E; Ciccarelli M; Carrizzo A; Vecchione C
    Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets.
    Tanase DM; Gosav EM; Petrov D; Jucan AE; Lacatusu CM; Floria M; Tarniceriu CC; Costea CF; Ciocoiu M; Rezus C
    Diagnostics (Basel); 2021 Nov; 11(11):. PubMed ID: 34829402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceramides - Lipotoxic Inducers of Metabolic Disorders.
    Chaurasia B; Summers SA
    Trends Endocrinol Metab; 2015 Oct; 26(10):538-550. PubMed ID: 26412155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Lard Works in Mysterious Ways: Ceramides in Nutrition-Linked Chronic Disease.
    Nicholson RJ; Norris MK; Poss AM; Holland WL; Summers SA
    Annu Rev Nutr; 2022 Aug; 42():115-144. PubMed ID: 35584813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of specific ceramides to obesity-associated metabolic diseases.
    Hammerschmidt P; Brüning JC
    Cell Mol Life Sci; 2022 Jul; 79(8):395. PubMed ID: 35789435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceramides are necessary and sufficient for diet-induced impairment of thermogenic adipocytes.
    Chaurasia B; Ying L; Talbot CL; Maschek JA; Cox J; Schuchman EH; Hirabayashi Y; Holland WL; Summers SA
    Mol Metab; 2021 Mar; 45():101145. PubMed ID: 33352310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingolipids as a Culprit of Mitochondrial Dysfunction in Insulin Resistance and Type 2 Diabetes.
    Roszczyc-Owsiejczuk K; Zabielski P
    Front Endocrinol (Lausanne); 2021; 12():635175. PubMed ID: 33815291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification.
    Hilvo M; Vasile VC; Donato LJ; Hurme R; Laaksonen R
    Front Endocrinol (Lausanne); 2020; 11():570628. PubMed ID: 33133018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance.
    Lipina C; Hundal HS
    Diabetologia; 2011 Jul; 54(7):1596-607. PubMed ID: 21468641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceramides in Metabolism: Key Lipotoxic Players.
    Chaurasia B; Summers SA
    Annu Rev Physiol; 2021 Feb; 83():303-330. PubMed ID: 33158378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors.
    Meeusen JW; Donato LJ; Kopecky SL; Vasile VC; Jaffe AS; Laaksonen R
    Clin Chim Acta; 2020 Dec; 511():138-142. PubMed ID: 33058843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of sphingolipids in selected cardiovascular diseases].
    Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Chabowska A; Łukaszuk B; Żendzian-Piotrowska M
    Postepy Hig Med Dosw (Online); 2013 Sep; 67():1018-26. PubMed ID: 24088546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceramide Metabolism Balance, a Multifaceted Factor in Critical Steps of Breast Cancer Development.
    García-González V; Díaz-Villanueva JF; Galindo-Hernández O; Martínez-Navarro I; Hurtado-Ureta G; Pérez-Arias AA
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of sphingolipid metabolism augments ceramide-induced autophagy in preeclampsia.
    Melland-Smith M; Ermini L; Chauvin S; Craig-Barnes H; Tagliaferro A; Todros T; Post M; Caniggia I
    Autophagy; 2015 Apr; 11(4):653-69. PubMed ID: 25853898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingolipids in mitochondria.
    Hernández-Corbacho MJ; Salama MF; Canals D; Senkal CE; Obeid LM
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Jan; 1862(1):56-68. PubMed ID: 27697478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of plasma sphingolipids as mediators of the relationship between kidney disease and cardiovascular events.
    Lidgard B; Bansal N; Zelnick LR; Hoofnagle AN; Fretts AM; Longstreth WT; Shlipak MG; Siscovick DS; Umans JG; Lemaitre RN
    EBioMedicine; 2023 Sep; 95():104765. PubMed ID: 37634384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.